About This Article
This study aimed to investigate whether MBX-2982, a GPR119 receptor agonist, could enhance the body’s hormonal defenses against hypoglycemia in individuals with type 1 diabetes. GPR119 receptors are found on specific cells in the gut and pancreas and are thought to play a role in regulating blood sugar by influencing hormone release. Researchers conducted a controlled clinical trial involving 18 adults with type 1 diabetes to test whether activating these receptors with MBX-2982 would strengthen counterregulatory responses—such as the release of glucagon—during low blood sugar conditions, as well as examine its effects on hormone levels after eating.
Marcus Hompesch, MD, ProSciento CEO, was a contributor to this study.
